Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L L Siu

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
New drug development in digestive neuroendocrine tumorsI Durán, R Salazar, O Casanovas, et al.
British Journal of Haematology|February 13, 2001
Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemiaW Y Au, A K Lie, S K Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinomaL L Siu, D Banerjee, R J Khurana, et al.
ESMO Open|July 23, 2024
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I studyA Algazi, K P Papadopoulos, F Tsai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2011
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACCN G Chau, S J Hotte, E X Chen, et al.
British Journal of Cancer|August 14, 2003
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursX Chen, A M Oza, Z Kusenda, et al.
Human Pathology|February 1, 1997
T- and T/natural killer-cell lymphomas of the salivary gland: a clinicopathologic, immunohistochemical and molecular study of six casesJ K Chan, W Y Tsang, P K Hui, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
British Journal of Cancer|November 14, 2014
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177E X Chen, S Hotte, H Hirte, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
New drug development in digestive neuroendocrine tumorsI Durán, R Salazar, O Casanovas, et al.
British Journal of Haematology|February 13, 2001
Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemiaW Y Au, A K Lie, S K Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinomaL L Siu, D Banerjee, R J Khurana, et al.
ESMO Open|July 23, 2024
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I studyA Algazi, K P Papadopoulos, F Tsai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2011
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACCN G Chau, S J Hotte, E X Chen, et al.
British Journal of Cancer|August 14, 2003
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursX Chen, A M Oza, Z Kusenda, et al.
Human Pathology|February 1, 1997
T- and T/natural killer-cell lymphomas of the salivary gland: a clinicopathologic, immunohistochemical and molecular study of six casesJ K Chan, W Y Tsang, P K Hui, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
British Journal of Cancer|November 14, 2014
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177E X Chen, S Hotte, H Hirte, et al.
Pageof 9